Nadir Yalcin

Dr. Nadir Yalcin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
NYNadir Yalcin
Nadir Yalcin
MKMerve Kaşıkcı
Merve Kaşıkcı
HÇHasan Tolga Çelik
Hasan Tolga Çelik
KAKarel Allegaert
Karel Allegaert
KDKutay Demirkan
Kutay Demirkan
MYMurat Yurdakök
Murat Yurdakök
Aim: To develop models that predict the presence of medication errors (MEs) (prescription, preparation, administration, and monitoring) using machine learning in NICU patients.Design: Prospective, observational cohort study randomized with machine learning (ML) algorithms.Setting: A 22-bed capacity NICU in Ankara, Turkey, between February 2020 and July 2021.Results: A total of 11,908 medication orders (28.9 orders/patient) for 412 NICU patients (5.53 drugs/patient/day) who received 2,280 prescriptions over 32,925 patient days were analyzed. At least one physician-related ME and nurse-related ME were found in 174 (42.2%) and 235 (57.0%) of the patients, respectively. The parameters that had the highest correlation with ME occurrence and subsequently included in the model were: total number of drugs, anti-infective drugs, nervous system drugs, 5-min APGAR score, postnatal age, alimentary tract and metabolism drugs, and respiratory system drugs as patient-related parameters, and weekly working hours of nurses, weekly working hours of physicians, and number of nurses’ monthly shifts as care provider-related parameters. The obtained model showed high performance to predict ME (AUC: 0.920; 95% CI: 0.876–0.970) presence and is accessible online (http://softmed.hacettepe.edu.tr/NEO-DEER_Medication_Error/).Conclusion: This is the first developed and validated model to predict the presence of ME using work environment and pharmacotherapy parameters with high-performance ML algorithms in NICU patients. This approach and the current model hold the promise of implementation of targeted/precision screening to prevent MEs in neonates.Clinical Trial Registration:ClinicalTrials.gov, identifier NCT04899960.

26 November 2022 in Children
Verified
Journal Article
Open access
PDF file
NYNadir Yalcin
Nadir Yalcin
MKMerve Kaşıkcı
Merve Kaşıkcı
HÇHasan Tolga Çelik
Hasan Tolga Çelik
Karel AllegaertKarel Allegaert
Karel Allegaert
KDKutay Demirkan
Kutay Demirkan
MYMurat Yurdakök
Murat Yurdakök
Background: Critically ill neonates are at greater risk for adverse drug reactions (ADRs). The differentiation of ADRs from reactions associated with organ dysfunction/immaturity or genetic variability is difficult. Methods: In this prospective cohort study, each ADR was assessed using newborn-specific severity and probability scales by the clinical pharmacist. Subsequently, a machine learning-based risk score was designed to predict ADR presence in neonates. Results: In 98/412 (23.8%) of (56.3%; male) neonates included, 187 ADRs (0.42 ADR/patient) were determined related to 49 different drugs (37.12%). Drugs identified as high risk were enoxaparin, dexmedetomidine, vinblastine, dornase alfa, etoposide/carboplatin and prednisolone. The independent variables included in the risk score to predict ADR presence, according to the random forest importance criterion, were: systemic hormones (2 points), cardiovascular drugs (3 points), diseases of the circulatory system (1 point), nervous system drugs (1 point), and parenteral nutrition treatment (1 point), (cut-off value: 3 points). This risk score correctly classified 91.1% of the observations in the test set (c-index: 0.914). Conclusions: Using the high-performing risk score specific to neonates, it is expected that high-risk neonatal ADRs can be determined and prevented before they occur. Moreover, the awareness of clinicians of these drugs can be improved with this web-tool, and mitigation strategies (change of drug, dose, treatment duration, etc.) can be considered, based on a benefit-harm relationship for suspected drugs with a newborn-centered approach.

29 July 2022 in Cambridge Prisms: Global Mental Health
Verified
Journal Article
Open access
PDF file
NYNadir Yalcin
Nadir Yalcin
IBIzgi Bayraktar
Izgi Bayraktar
EKErdem Karabulut
Erdem Karabulut
Renato de FilippisRenato de Filippis
Renato de Filippis
FJFlorence Jaguga
Florence Jaguga
RRRodrigo Ramalho
Rodrigo Ramalho
Background: The COVID-19 pandemic has captured the mental health discussion worldwide. Examining countries' representation in this discussion could prove instrumental in identifying potential gaps in terms of ensuring a truly global conversation in times of global crisis.Methods: We collected mental health and COVID-19-related journal articles published in PubMed in 2020. We focused on the corresponding authors' countries of affiliation to explore countries' representation. We also examined these articles' academic impact and correlations with their corresponding authors' countries of affiliation. Additional journals and countries' indicators were collected from the Web of Science and World Bank websites, respectively. Data were analyzed using the IBM SPSS Statistics and the VOSviewer software.Results: In total, 3492 publications were analyzed. Based on the corresponding author, high-income countries produced 61.9% of these publications. Corresponding authors from Africa, Latin America and the Caribbean, and the Middle East combined accounted for 11.8% of the publications. Europe hosted corresponding authors with the most publications and citations, and corresponding authors from North America had the largest mean journal impact factor.Conclusions: The global scientific discussion during the COVID-19 pandemic saw an increased contribution of academics from developing countries. However, authors from high-income countries have continued to shape this discussion. It is imperative to ensure the active participation of low- and middle-income countries in setting up the global mental health research agenda, particularly in situations of global crisis, such as the ongoing pandemic.

30 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NYNadir Yalcin
Nadir Yalcin
MKMerve Kaşıkcı
Merve Kaşıkcı
HÇHasan Tolga Çelik
Hasan Tolga Çelik
KDKutay Demirkan
Kutay Demirkan
ŞYŞule Yiğit
Şule Yiğit
MYMurat Yurdakök
Murat Yurdakök
Hospitalized newborns have an increased risk of malnutrition and, especially preterm infants, often experience malnutrition-related extrauterine growth restriction (EUGR). The aim of this study was to predict the discharge weight and the presence of weight gain at discharge with machine learning (ML) algorithms. The demographic and clinical parameters were used to develop the models using fivefold cross-validation in the software-R with a neonatal nutritional screening tool (NNST). A total of 512 NICU patients were prospectively included in the study. Length of hospital stay (LOS), parenteral nutrition treatment (PN), postnatal age (PNA), surgery, and sodium were the most important variables in predicting the presence of weight gain at discharge with a random forest classification (AUROC:0.847). The AUROC of NNST-Plus, which was improved by adding LOS, PN, PNA, surgery, and sodium to NNST, increased by 16.5%. In addition, weight at admission, LOS, gestation-adjusted age at admission (> 40 weeks), sex, gestational age, birth weight, PNA, SGA, complications of labor and delivery, multiple birth, serum creatinine, and PN treatment were the most important variables in predicting discharge weight with an elastic net regression (R2 = 0.748). This is the first study on the early prediction of EUGR with promising clinical performance based on ML algorithms. It is estimated that the incidence of EUGR can be improved with the implementation of this ML-based web tool (http://www.softmed.hacettepe.edu.tr/NEO-DEER/) in clinical practice.

21 July 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
IBİzgi Bayraktar
İzgi Bayraktar
NYNadir Yalcin
Nadir Yalcin
KDKutay Demirkan
Kutay Demirkan

5 August 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NYNadir Yalcin
Nadir Yalcin
Karel AllegaertKarel Allegaert
Karel Allegaert